AstraZeneca PLC American Depositary Shares AZN
NASDAQ
$167.48
+1.40 (+0.84%)
A quick, factual read on the price trend and the underlying business, not a recommendation, and not a substitute for reading the numbers below yourself.
At a glance
39
Technical strength
Trend, momentum, position vs averages
- • Price is 8.5% below its 200-day moving average.
- • 14-day RSI is 57.
- • Sits at 32% of its 52-week range (0% = low, 100% = high).
68
Fundamental quality
Margins, returns, leverage, growth
- • Gross margin is 82.0%.
- • Return on equity is 16.1%.
- • Revenue grew 3.3% year over year.
$168.35
Open
$166.08
Previous close
$212.71
52-week high
$145.80
52-week low
57,869
Volume
3,099,947
Avg. volume
$164.27
50-day avg.
+28%
Volatility (ann.)
Context
- Trading 14.9% above its 52-week low, and closer to the bottom of its 52-week range.
- Trading 2.0% above its 50-day average price, consistent with recent upward momentum.
- Annualized price volatility over this period is about 28%, which is moderately volatile next to a typical broad-market stock (commonly ~15-25%).
About
AstraZeneca plc (AZ) is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
Fundamentals & valuation (FY2025, from SEC filings)
Core financials
$45.8bn
Revenue (latest FY)
+3.29%
Revenue growth (YoY)
$6.0bn
Net income (latest FY)
+81.95%
Gross margin
+17.88%
Operating margin
$3.81
EPS (diluted)
$5.8bn
Cash & equivalents
+13.01%
Net margin
+80.57%
EPS growth (YoY)
-$2.0bn
Working capital
$37.1bn
Shareholders' equity
$10.3bn
Operating cash flow
Valuation multiples
$167.48
Price
44.0x
P/E ratio
Growth & returns
+3.29%
Revenue growth (YoY)
+80.57%
EPS growth (YoY)
+16.09%
ROE
+5.73%
ROA
Credit metrics & WACC inputs
0.28
Beta (vs. S&P 500)
$5.8bn
Cash & equivalents
In the news
- AstraZeneca to complete direct listing of ordinary shares and all US debt securities on the New York Stock Exchange
AstraZeneca · 2026-01-20
- AstraZeneca to delist from Nasdaq, join NYSE in February
Reuters · 2026-01-19
- AstraZeneca (AZN) Shares to Start Trading in US After Listing Upgrade
Bloomberg.com · 2026-02-02
- Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca
Investopedia · 2026-08-03
- AstraZeneca lists on the NYSE on Monday, ending ADS program
Seeking Alpha · 2026-02-02
- AstraZeneca’s Strategic Leap: Pharmaceutical Giant Completes Historic Move to the New York Stock Exchange
FinancialContent · 2026-02-26
Want to go further?
Build your own investment report from this data. Pick a report type, add your thesis, and export a PDF.